US FDA’s Biologics Center Faces Exciting 2019 After Quiet Year For Novel Approvals
Executive Summary
CBER’s novel biologic approvals in 2018 were few, long, and with a low level of innovation. But the center’s work to build regulatory framework for emerging technologies is setting the stage for a different story in 2019.
You may also be interested in...
Keeping Track: Amarin And Nektar Signal Delays, DBV Returns, And Provention Notches A BTD
The latest drug development news and highlights from our US FDA Performance Tracker.
Keeping Track: Thumbs Up For Zulresso And Sunosi, Thumbs Down For Zynquista And IV Meloxicam
The latest drug development news and highlights from our US FDA Performance Tracker.
Keeping Track: Two Goal Date Extensions, Another Herceptin Biosimilar Approval, And A BLA Withdrawal
The latest drug development news and highlights from our US FDA Performance Tracker.